<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01201278</url>
  </required_header>
  <id_info>
    <org_study_id>NI2010-001</org_study_id>
    <nct_id>NCT01201278</nct_id>
  </id_info>
  <brief_title>PK/PD Study of Intranasal Insulin in Type I Diabetes</brief_title>
  <official_title>A Phase 1, Randomized, 3-Way Crossover, Investigator Initiated Proof-of-Concept Study to Investigate Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of Two Doses of Intranasally Administered Regular Human Insulin Compared to a Single Dose of a Subcutaneously Injected Rapid Acting Insulin Analog (Humalog®) in Subjects With Type I Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hompesch, Marcus, M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Profil Institute for Clinical Research, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hompesch, Marcus, M.D.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to compare the safety and tolerability of two different doses of&#xD;
      intranasally administered regular human insulin with those of a single dose of the&#xD;
      rapid-acting insulin analog lispro Humalog® after subcutaneous injection. In addition to&#xD;
      safety and tolerability, various pharmacokinetic (PK) and pharmacodynamic (PD) parameters&#xD;
      will be evaluated by means of the euglycemic glucose clamp technique.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Insulin tolerability, PK, and PD</measure>
    <time_frame>120 minutes</time_frame>
    <description>To assess safety and tolerability, and to compare the insulin AUC over 0-120 min for each of the three insulin applications.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>Nasal insulin 8 IU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nasal insulin at a dose estimated to be equivalent to 8 IU bioavailable insulin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nasal insulin 16 IU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nasal insulin at a dose estimated to be equivalent to 16 IU bioavailable insulin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subcutaneous insulin lispro 8 U</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subcutaneous insulin lispro (Humalog®) 8 U</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin</intervention_name>
    <description>Nasal insulin at a dose estimated to be equivalent to 8 IU bioavailable insulin</description>
    <arm_group_label>Nasal insulin 8 IU</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin</intervention_name>
    <description>Nasal insulin at a dose estimated to be equivalent to 16 IU bioavailable insulin</description>
    <arm_group_label>Nasal insulin 16 IU</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin LISPRO</intervention_name>
    <description>Subcutaneous insulin lispro 8 U</description>
    <arm_group_label>Subcutaneous insulin lispro 8 U</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male and female subjects with type 1 diabetes between the ages of 18 and 65 years,&#xD;
             inclusive.&#xD;
&#xD;
          2. Type 1 diabetes clinically diagnosed ≥ 12 months.&#xD;
&#xD;
          3. Treated with multiple daily insulin injections ≥ 12 months or an insulin pump.&#xD;
&#xD;
          4. HbA1c ≤ 10 % by local laboratory analysis (one retest within a week is permitted with&#xD;
             the result of the last test being conclusive).&#xD;
&#xD;
          5. Fasting serum C-peptide ≤ 0.3 nmol/L.&#xD;
&#xD;
          6. BMI between 18-28 kg/m², inclusive.&#xD;
&#xD;
          7. Signed, written IRB-approved informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Evidence or history of clinically significant hematological, renal, endocrine,&#xD;
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, oncologic, or&#xD;
             neurologic (to include history of seizures) disease; hypoglycemic episodes;&#xD;
             intercurrent illness (such as influenza); or allergic disease (including severe drug&#xD;
             allergies, but excluding untreated, asymptomatic, seasonal allergies at time of&#xD;
             dosing). Clinical significance to be determined by the PI.&#xD;
&#xD;
          2. History of recent nose bleed, history of nasal polyps, nasal surgery other than&#xD;
             cosmetic rhinoplasty or cauterization.&#xD;
&#xD;
          3. As judged by the investigator, clinically significant findings in laboratory data.&#xD;
             (Anemia with hematocrit less than 33% at screening is specifically exclusionary.)&#xD;
&#xD;
          4. Clinically significant abnormal ECG at screening, as judged by the Investigator.&#xD;
&#xD;
          5. Clinically significant abnormalities in vital signs at screening, as judged by the&#xD;
             Investigator.&#xD;
&#xD;
          6. Known allergy to trial product or any other ingredient in the study drug.&#xD;
&#xD;
          7. Positive HIV 1 (human immunodeficiency virus) antibody test, hepatitis B (anti-HBsAg)&#xD;
             or hepatitis C (anti-HCV) antibody test.&#xD;
&#xD;
          8. History or evidence of alcohol or drug abuse within the past 3 years.&#xD;
&#xD;
          9. History of deep leg vein thrombosis or a frequent appearance of deep leg vein&#xD;
             thrombosis in 1st degree relatives (parents, siblings or children) as judged by the&#xD;
             Investigator.&#xD;
&#xD;
         10. Use of drugs that may interfere with the interpretation of study results or are known&#xD;
             to cause clinically relevant interference with insulin action or glucose utilization.&#xD;
&#xD;
         11. Blood donation or high volume phlebotomy, e.g., &gt;500 mL, within 56 days before dosing.&#xD;
&#xD;
         12. Participation in a study of any investigational drug or device 30 days before&#xD;
             enrollment in this study.&#xD;
&#xD;
         13. The subject is unfit for the study in the opinion of the investigator.&#xD;
&#xD;
         14. Female of childbearing potential who is pregnant, breast-feeding or intends to become&#xD;
             pregnant or is not using adequate contraceptive methods (adequate contraceptive&#xD;
             measures include sterilization, hormonal intrauterine devices, oral contraceptives,&#xD;
             sexual abstinence or vasectomized partner).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Marcus Hompesch, MD</last_name>
    <phone>(619) 427-1300</phone>
    <email>marcus.hompesch@profilinstitute.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Profil Institute for Clinical Research</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91911</zip>
        <country>United States</country>
      </address>
    </facility>
    <investigator>
      <last_name>Marcus Hompesch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <study_first_submitted>September 13, 2010</study_first_submitted>
  <study_first_submitted_qc>September 13, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2010</study_first_posted>
  <last_update_submitted>June 15, 2011</last_update_submitted>
  <last_update_submitted_qc>June 15, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 17, 2011</last_update_posted>
  <responsible_party>
    <name_title>Hompesch, Marcus, M.D.</name_title>
    <organization>Profil Institute for Clinical Research, Inc.</organization>
  </responsible_party>
  <keyword>intranasal insulin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin Lispro</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

